Doral is owned by Galt Pharms.
Doral contains Quazepam.
Doral has a total of 1 drug patent out of which 0 drug patents have expired.
Doral was authorised for market use on 27 December, 1985.
Doral is available in tablet;oral dosage forms.
Doral can be used as method for treating insomnia while reducing the risk of an adverse drug interaction.
The generics of Doral are possible to be released after 03 June, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7608616||GALT PHARMS||Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia|| |
(5 years from now)
Market Authorisation Date: 27 December, 1985
Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic